Implications of maraviroc and/or rapamycin in a mouse model of fragility | Zendy

Laura PérezMartínez | Zendy; Lourdes Romero | Zendy; Sandra Muñoz-Galván | Zendy; Eva M. VerdugoSivianes | Zendy; Susana Rubio-Mediavilla | Zendy; José A. Oteo | Zendy; Amancio Carnero | Zendy; José Ramón Blanco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Implications of maraviroc and/or rapamycin in a mouse model of fragility

Author(s) -

Laura PérezMartínez,

Lourdes Romero,

Sandra Muñoz-Galván,

Eva M. VerdugoSivianes,

Susana Rubio-Mediavilla,

José A. Oteo,

Amancio Carnero,

José Ramón Blanco

Publication year - 2020

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.103167

Subject(s) - medicine , gastroenterology , biology , immunology

As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10 tm/tm [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research